

T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

28 July 2025

Dear Healthcare Professional,

DRUG ALERT CLASS 2 – No 36 2025 – CLASS 2 MEDICINES RECALL – ACTION WITHIN 48 HOURS – BECTON DICKINSON UK LTD – CHLORAPREP 1ML CLEAR STERILE SOLUTION/APPLICATOR

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team



MEDICINES RECALL

CLASS 2 MEDICINES RECALL, EL(25)A/36

Action within 48 hours

Issued 28 July 2025

Distribute to Pharmacy/Wholesaler Level

MARKETING AUTHORISATION HOLDER (MAH)

Becton Dickinson UK Ltd

MEDICINE DETAILS

ChloraPrep 1mL Clear Sterile Solution/Applicator

PL: **PL05920/0002**

Active Ingredient: **chlorhexidine gluconate 2%w/v and isopropyl alcohol 70% v/v**

SNOMED code: **40818011000001105**

GTIN: **20885403491761**

AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
4255106	30/09/2027	60	10/03/2025

Background

Becton Dickinson UK Ltd has informed the MHRA that some units exhibit an open seal on the packaging of the applicator. This issue is linked to the previous Class 2 Medicines Notification EL(25)A/22. This defect could increase the risk of the applicator device being contaminated with pathogens, which could lead to increased infection rates for the patients.

The number of impacted units in the batch is unknown, therefore the batch in the table is being recalled as a precautionary measure. This recall does not impact other batches of BD ChloraPrep Clear - 1mL Applicator that remain available for clinical use.

Advice for Healthcare Professionals:

Stop supplying the affected batches. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for Healthcare Professionals to Provide to Patients:

No further action is required by patients as this product is used by healthcare professionals only and they will have taken the action to remove this product from use.

The recall is a precautionary measure to mitigate any additional risk of infection.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information:

For all medical information enquiries and information on this product, please email safetyinformation@bd.com, or telephone 08000437546.

For stock control enquiries please email info@insightbio.com, or telephone 01707351330.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk